Intact Genomics, Inc.

Intact Genomics, Inc. is a biotech company based in St. Louis, Missouri, USA. The company specializes in providing custom genomic services including unbiased bacterial artificial chromosome (BAC) libraries and DNA library screening, along with life science products such as enzymes and competent cells for gene discovery and genomic research. Founded in 2013 by Dr. Chengcang (Cheng-Cang) Charles Wu, the company received a $2.94M grant investment from the National Institute of Allergy and Infectious Diseases in July 2022. Intact Genomics focuses on genomic technology innovation and applies large DNA fragment cloning technologies in metagenomic research for agricultural research, natural product-enzyme discovery, and environmental protection. The company's team of scientists is highly experienced and committed to providing personalized services with fast turnaround times and reasonable prices. The company's dedication to advancing genome structure and function exploration in microorganisms, plants, and animal species positions it as an essential player in the biopharma, biotechnology, and healthcare industries. With its strong expertise and recent funding, Intact Genomics is well-positioned to continue making significant contributions to the field of genomic research and applications.